Artemis Medicare Services Intrinsic Value
Artemis Medicare Services (ARTEMISMED) median intrinsic value is ₹558.62 from 9 valuation models (range ₹84–₹698), vs current price ₹279.31 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Also explore ARTEMISMED share price charts to track price trends across different timeframes.
ARTEMISMED Valuation Methods Summary — DCF, Graham Number & P/E
Artemis Medicare Services intrinsic value across 9 models vs current price ₹279.31 — upside/downside and value range per method. Browse ARTEMISMED cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹91.20 | ₹72.96 - ₹109.44 | -67.3% | EPS: ₹7.60, Sector P/E: 12x |
| Book Value Method | asset | ₹584.38 | ₹525.94 - ₹642.82 | +109.2% | Book Value/Share: ₹584.38, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹558.62 | ₹502.76 - ₹614.48 | +100.0% | Revenue/Share: ₹717.50, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹558.62 | ₹502.76 - ₹614.48 | +100.0% | EBITDA: ₹236.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹698.27 | ₹558.62 - ₹837.92 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹83.79 | ₹75.41 - ₹92.17 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹83.79 | ₹75.41 - ₹92.17 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹558.62 | ₹502.76 - ₹614.48 | +100.0% | ROE: 12.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹316.11 | ₹284.50 - ₹347.72 | +13.2% | EPS: ₹7.60, BVPS: ₹584.38 |
ARTEMISMED Intrinsic Value vs Market Price — All Valuation Models
Artemis Medicare Services fair value range ₹84–₹698 vs current market price ₹279.31 across 9 valuation models. For current market price and key ratios, visit Artemis Medicare Services share price today.
ARTEMISMED Intrinsic Value Analysis — Undervalued or Overvalued?
Artemis Medicare Services median intrinsic value ₹558.62, current price ₹279.31 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ARTEMISMED?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Artemis Medicare Services (ARTEMISMED) is ₹558.62 (median value). With the current market price of ₹279.31, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹83.79 to ₹698.27, indicating ₹83.79 - ₹698.27.
Is ARTEMISMED undervalued or overvalued?
Based on our multi-method analysis, Artemis Medicare Services (ARTEMISMED) appears to be trading below calculated value by approximately 100.0%.
ARTEMISMED Financial Health — Key Ratios vs Industry Benchmarks
Artemis Medicare Services financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.32 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 12.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.80x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ARTEMISMED Cash Flow Quality — Operating & Free Cash Flow
Artemis Medicare Services operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹146 Cr | ₹-47 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹109 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹127 Cr | ₹48 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹60 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹27 Cr | ₹9 Cr | Positive Free Cash Flow | 7/10 |